Geneva Capital Management LLC trimmed its holdings in Bio-Techne Corp (NASDAQ:TECH – Free Report) by 12.6% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 884,168 shares of the biotechnology company’s stock after selling 127,909 shares during the quarter. Bio-Techne accounts for about 1.8% of Geneva Capital Management LLC’s holdings, making the stock its 19th biggest holding. Geneva Capital Management LLC owned approximately 0.56% of Bio-Techne worth $64,076,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the business. Financial Freedom LLC purchased a new stake in Bio-Techne during the third quarter valued at about $30,000. Aberdeen Group plc grew its stake in shares of Bio-Techne by 24.8% during the third quarter. Aberdeen Group plc now owns 8,418 shares of the biotechnology company’s stock valued at $610,000 after buying an additional 1,672 shares during the last quarter. First Trust Capital Management L.P. bought a new position in shares of Bio-Techne during the third quarter valued at about $1,724,000. R Squared Ltd purchased a new position in shares of Bio-Techne in the third quarter worth about $539,000. Finally, Maryland State Retirement & Pension System increased its holdings in shares of Bio-Techne by 10.7% in the third quarter. Maryland State Retirement & Pension System now owns 9,205 shares of the biotechnology company’s stock worth $667,000 after buying an additional 891 shares during the period. 98.95% of the stock is currently owned by institutional investors.
Bio-Techne Stock Performance
TECH stock opened at $72.80 on Monday. The firm’s 50-day moving average price is $72.53 and its two-hundred day moving average price is $63.48. Bio-Techne Corp has a 12-month low of $43.19 and a 12-month high of $72.88. The stock has a market capitalization of $11.44 billion, a price-to-earnings ratio of 66.79, a PEG ratio of 5.28 and a beta of 1.29.
Bio-Techne (NASDAQ:TECH – Get Free Report) last posted its earnings results on Monday, November 9th. The biotechnology company reported $0.44 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.44. The company had revenue of $299.71 million during the quarter, compared to analyst estimates of $292.60 million. Bio-Techne had a net margin of 13.95% and a return on equity of 13.00%. Equities analysts predict that Bio-Techne Corp will post 1.75 EPS for the current year.
Bio-Techne Cuts Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, November 23rd. Shareholders of record on Friday, November 13th will be given a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 13th. This is a negative change from Bio-Techne’s previous quarterly dividend of $0.65. Bio-Techne’s dividend payout ratio is currently 29.36%.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on TECH shares. Benchmark reissued a “hold” rating on shares of Bio-Techne in a research note on Wednesday, August 19th. Argus lowered Bio-Techne from a “strong-buy” rating to a “strong sell” rating in a research report on Monday, October 26th. Weiss Ratings upgraded Bio-Techne from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Zacks Research raised Bio-Techne from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 29th. Finally, Wells Fargo & Company downgraded Bio-Techne from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $62.00 to $73.00 in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $68.92.
Check Out Our Latest Stock Analysis on TECH
Bio-Techne Company Profile
Bio-Techne is a life sciences company that develops and supplies products and services used in biological research, drug development, and clinical diagnostics. Its offerings include proteins, antibodies, immunoassays, and small molecules, as well as instruments and analytical tools for studying cells and biological processes. The company also provides technologies for protein analysis, molecular diagnostics, and spatial biology. Its portfolio includes products and services associated with brands such as R&D Systems, Tocris, ProteinSimple, and Advanced Cell Diagnostics.
See Also
- Five stocks we like better than Bio-Techne
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
